Latest Conference Articles

September 7th 2022, 1:35pm

International Liver Cancer Association Annual Conference

Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.

September 6th 2022, 10:23pm

International Liver Cancer Association Annual Conference

Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.

September 6th 2022, 5:35pm

International Liver Cancer Association Annual Conference

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

September 4th 2022, 1:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

August 28th 2022, 3:24pm

International Myeloma Society Annual Meeting

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

August 28th 2022, 2:51pm

International Myeloma Society Annual Meeting

Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

August 28th 2022, 2:37pm

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

August 28th 2022, 2:37pm

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

August 28th 2022, 2:36pm

International Myeloma Society Annual Meeting

Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.

August 28th 2022, 1:27am

International Myeloma Society Annual Meeting

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.

August 28th 2022, 1:00am

International Myeloma Society Annual Meeting

High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.

August 28th 2022, 12:49am

International Myeloma Society Annual Meeting

Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.

August 27th 2022, 7:55pm

International Myeloma Society Annual Meeting

Relapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.

August 27th 2022, 6:30pm

International Myeloma Society Annual Meeting

The addition of isatuximab to pomalidomide and low-dose dexamethasone continued to demonstrate improved overall survival in patients with relapsed/refractory multiple myeloma.

August 27th 2022, 5:36pm

International Myeloma Society Annual Meeting

The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.

August 27th 2022, 5:24pm

International Myeloma Society Annual Meeting

REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

August 27th 2022, 5:21pm

International Myeloma Society Annual Meeting

Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.

August 27th 2022, 2:10pm

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

August 27th 2022, 2:10pm

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

August 27th 2022, 2:04pm

International Myeloma Society Annual Meeting

Cevostamab generated responses and was well tolerated in younger and older patients with relapsed/refractory multiple myeloma.